AU2017268291B2 - PET-imaging immunomodulators - Google Patents

PET-imaging immunomodulators Download PDF

Info

Publication number
AU2017268291B2
AU2017268291B2 AU2017268291A AU2017268291A AU2017268291B2 AU 2017268291 B2 AU2017268291 B2 AU 2017268291B2 AU 2017268291 A AU2017268291 A AU 2017268291A AU 2017268291 A AU2017268291 A AU 2017268291A AU 2017268291 B2 AU2017268291 B2 AU 2017268291B2
Authority
AU
Australia
Prior art keywords
compound
ethoxy
subject
disease
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017268291A
Other languages
English (en)
Other versions
AU2017268291A1 (en
Inventor
Kenneth M. Boy
David J. Donnelly
Joonyoung Kim
Adrienne PENA
Yunhui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2017268291A1 publication Critical patent/AU2017268291A1/en
Application granted granted Critical
Publication of AU2017268291B2 publication Critical patent/AU2017268291B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/12—Arrangements for detecting or locating foreign bodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017268291A 2016-05-19 2017-05-17 PET-imaging immunomodulators Active AU2017268291B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338872P 2016-05-19 2016-05-19
US62/338,872 2016-05-19
PCT/US2017/033004 WO2017201111A1 (en) 2016-05-19 2017-05-17 Pet-imaging immunomodulators

Publications (2)

Publication Number Publication Date
AU2017268291A1 AU2017268291A1 (en) 2019-01-17
AU2017268291B2 true AU2017268291B2 (en) 2022-09-29

Family

ID=59021563

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017268291A Active AU2017268291B2 (en) 2016-05-19 2017-05-17 PET-imaging immunomodulators

Country Status (25)

Country Link
US (2) US11103605B2 (https=)
EP (2) EP3458111B1 (https=)
JP (1) JP6953444B2 (https=)
KR (1) KR102378288B1 (https=)
CN (1) CN109414514B (https=)
AU (1) AU2017268291B2 (https=)
BR (1) BR112018073642A2 (https=)
CA (1) CA3024844A1 (https=)
CY (1) CY1124241T1 (https=)
DK (1) DK3458111T3 (https=)
EA (1) EA038019B1 (https=)
ES (1) ES2864091T3 (https=)
HR (1) HRP20210644T8 (https=)
HU (1) HUE054306T2 (https=)
IL (1) IL262962B (https=)
LT (1) LT3458111T (https=)
MA (1) MA53402A (https=)
MX (1) MX2018014028A (https=)
PL (1) PL3458111T3 (https=)
PT (1) PT3458111T (https=)
RS (1) RS61742B1 (https=)
SG (1) SG11201810177VA (https=)
SI (1) SI3458111T1 (https=)
SM (1) SMT202100238T1 (https=)
WO (1) WO2017201111A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
EP4649966A3 (en) 2016-12-01 2026-02-18 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
KR20240023665A (ko) * 2016-12-23 2024-02-22 더 존스 홉킨스 유니버시티 Pd-l1 발현에 기반한 종양 및 면역 세포 영상화
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
SG11202000073XA (en) 2017-07-24 2020-02-27 Regeneron Pharma Anti-cd8 antibodies and uses thereof
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂
CN110504017B (zh) * 2019-07-30 2022-06-10 哈尔滨医科大学 一种示踪剂的制备和使用方法
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
EP4087857B1 (en) 2020-01-06 2023-11-01 Bristol-Myers Squibb Company Immunomodulators
KR20220155332A (ko) * 2020-03-16 2022-11-22 브리스톨-마이어스 스큅 컴퍼니 면역조정제
KR20220161407A (ko) 2020-03-30 2022-12-06 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US12159403B2 (en) * 2021-06-18 2024-12-03 The United States Government As Represented By The Department Of Veteran Affairs Combination of features from biopsies and scans to predict prognosis in SCLC
KR20250117435A (ko) * 2022-12-12 2025-08-04 머크 샤프 앤드 돔 엘엘씨 그랜자임 b의 pet 영상화제로서의 시클릭 펩티드

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151634A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5128119A (en) 1989-06-12 1992-07-07 Immunomedics, Inc. Methods for technetium/rhenium labeling of f(ab1)2 fragments
US5328679A (en) 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5746996A (en) 1994-06-03 1998-05-05 Immunomedics, Inc. Thiolation of peptides for radionuclide-based radiodetection and radiotherapy
IL113610A0 (en) 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5753206A (en) 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP0954340B1 (en) 1996-05-03 2007-06-27 Immunomedics, Inc. Targeted combination immunotherapy of cancer
EP0975374B1 (en) 1996-07-12 2007-12-05 Immunomedics, Inc. Radiometal-binding peptide analogues
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US6187284B1 (en) 1997-09-03 2001-02-13 Immunomedics, Inc. Fluorination of proteins and peptides for F-18 positron emission tomography
JP5605602B2 (ja) 2007-03-26 2014-10-15 国立大学法人 東京大学 環状ペプチド化合物の合成方法
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
EP2647720B1 (en) 2010-12-03 2019-06-19 The University of Tokyo Peptide library production method, peptide library, and screening method
WO2012168944A1 (en) 2011-06-08 2012-12-13 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013010573A1 (en) * 2011-07-18 2013-01-24 Universitaet Muenster Compounds with matrix-metalloproteinase inhibitory activity
CA2868408A1 (en) 2012-03-29 2013-10-03 Aurigene Discovery Technologies Limited Immunomodulating cyclic compounds from the bc loop of human pd1
JP2013253842A (ja) 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
JP6047231B2 (ja) 2012-06-06 2016-12-21 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ β−ヘアピンペプチド模倣薬
BR112015023120A2 (pt) 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
HRP20181271T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Ciklički peptidomimetički spojevi kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
WO2016039749A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
CA2969067A1 (en) * 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
EP3642220A1 (en) 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
CN111051332B (zh) 2017-10-03 2024-09-06 百时美施贵宝公司 免疫调节剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151634A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Maute, Roy L., et al. "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging." Proceedings of the National Academy of Sciences, 2015, 112(47), pp: E6506-E6514. *

Also Published As

Publication number Publication date
PT3458111T (pt) 2021-04-09
IL262962A (en) 2018-12-31
EA038019B1 (ru) 2021-06-23
JP2019520328A (ja) 2019-07-18
DK3458111T3 (da) 2021-04-26
MA53402A (fr) 2021-06-02
EA201892635A1 (ru) 2019-04-30
US20190117801A1 (en) 2019-04-25
EP3827849A1 (en) 2021-06-02
SMT202100238T1 (it) 2021-05-07
CA3024844A1 (en) 2017-11-23
PL3458111T3 (pl) 2021-06-28
KR20190009330A (ko) 2019-01-28
SG11201810177VA (en) 2018-12-28
IL262962B (en) 2020-04-30
HRP20210644T1 (hr) 2021-05-28
US11103605B2 (en) 2021-08-31
US20210386876A1 (en) 2021-12-16
WO2017201111A1 (en) 2017-11-23
HUE054306T2 (hu) 2021-08-30
ES2864091T3 (es) 2021-10-13
EP3458111B1 (en) 2021-03-03
EP3458111A1 (en) 2019-03-27
MX2018014028A (es) 2019-04-04
BR112018073642A2 (pt) 2019-02-26
AU2017268291A1 (en) 2019-01-17
JP6953444B2 (ja) 2021-10-27
CY1124241T1 (el) 2022-07-22
HRP20210644T8 (hr) 2021-06-25
CN109414514B (zh) 2022-03-11
SI3458111T1 (sl) 2021-07-30
LT3458111T (lt) 2021-05-25
RS61742B1 (sr) 2021-05-31
KR102378288B1 (ko) 2022-03-23
CN109414514A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
AU2017268291B2 (en) PET-imaging immunomodulators
JP7027480B2 (ja) 生物学的製剤の１８ｆ－放射性標識方法および組成物
US20220202966A1 (en) Positron emitting radionuclide labeled peptides for human upar pet imaging
EP4537851A1 (en) Trifunctional compound and use thereof
US20190184042A1 (en) Pet imaging with pd-l1 binding polypeptides
Lamba et al. Synthetic 18 F labeled biomolecules that are selective and promising for PET imaging: major advances and applications
Oum et al. A benzenesulfonamide derivative as a novel PET radioligand for CXCR4
JP2008531988A (ja) 放射性標識ガリウム錯体、その合成法並びに悪性腫瘍におけるｅｇｆｒ発現のｐｅｔイメージングにおける使用
CN117813326A (zh) 基于放射的导蛋白-1的检测、伴随测试和治疗方法
CN103275188B (zh) 放射性标记t140类多肽化合物及其制备方法和应用
Morgan Design and Synthesis of Radioactive Metal Complexes for the Diagnosis and Treatment of Disease
Sarrett The Development of Novel Radioimmunoconjugates for the PET Imaging and Radioimmunotherapy of Cancer
CA2968961C (en) Methods and compositions for 18f-radiolabeling of biologics
WO2026083399A1 (en) Conjugates and use of same for theranostics
AU2024344671A1 (en) Functionalized peptides for in-vivo addressing of pd-l1 expression
CN121699010A (zh) 抗pd-l2纳米抗体及其应用
BR112017010414B1 (pt) Sondas baseadas em proteína radiomarcada com 18f e composições farmacêuticas

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)